Torrent Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Aman Mehta as Managing Director of the company w.e.f. August 01, 2025.
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharmaceuticals has appointed Mr. Aman Mehta, currently a Whole-time Director, as the new Managing Director for a 5-year term starting August 1, 2025, subject to shareholder approval. The board also approved audited Q4 and FY25 results with standalone net profit of Rs. 474 crore for Q4 (up from Rs. 410 crore YoY) and Rs. 1,888 crore for FY25 (vs Rs. 1,357 crore prior year). The board recommended a final dividend of Rs. 6 per share (120%) on top of the Rs. 26 interim dividend already paid, taking total FY25 dividend to Rs. 32 per share. The company is also seeking shareholder approval to raise up to Rs. 5,000 crore through QIP or other modes.
The MD appointment is an internal elevation with continuity, which investors generally view as positive for stability. Strong FY25 earnings growth (standalone net profit up ~39% YoY) and the equity fundraising plan signal confidence in growth opportunities, though the QIP could lead to some dilution concerns once priced.